Safety-wise, no serious adverse events have been reported in short-term use, but long-term data is lacking 4
Like Reply 1 Reaction See more comments To view or add a comment, sign in 285,489 followers View Profile Follow More from this author A Strong Heart, A Better Tomorrow MSN Laboratories 1y Navratri Celebrations at MSN Laboratories MSN Laboratories 1y Empowering the Next Generation: MSN Laboratories Commitment to Youth Development through Self-Directed Teams MSN Laboratories 1y Explore content categories Career Productivity Finance Soft Skills & Emotional Intelligence Project Management Education Technology Leadership Ecommerce User Experience
Most people starting Zepbound experience some gastrointestinal side effects
Overall, repeat reporters leaned similar or mixed compared to their previous entry
We report the design and baseline data for FLOW (NCT03819153), a trial investigating the effects of semaglutide, a once-weekly (OW) GLP-1RA, on kidney outcomes in participants with CKD and T2D
Listed below is a timeline of legal events concerning GLP-1 receptor agonists
